Research Article Details
| Article ID: | A16191 |
| PMID: | 28511161 |
| Source: | Wiad Lek |
| Title: | [The diagnostics and clinical pattern of nonalcoholic fatty liver disease in patients with pre-diabetes and type 2 diabetes and obesity]. |
| Abstract: | INTRODUCTION: The data of epidemiological researches confirm the tendency in increasing of non alcoholic fatty liver disease (NAFLD) in patients with insulin resistance which occurs because of obesity, diabetes type 2 and metabolic syndrome. AIM: Optimization of diagnostic and treatment efficacy in patients with non alcoholic steatosis and steatohepatitis on the background of obesity. MATERIALS AND METHODS: General clinical examination of patients, laboratory and instrumental methods ( fatty liver index, non invasive assessment of liver, morphology, electrocardiography, treadmillergometry, ultrasound examination of abdominal organs, liver elastography,CT,MRI, methods of statistical analysis. RESULTS: NAFLD was diagnosed in 98.4% of patients with diabetes type 2, from which steatosis was found in 54.84% and steatohepatitis in 45.16%. In individuals with prediabetes NAFLD was in 70.5%, of which 85.45% with steatosis and 14.55% steatohepatitis (p<0.05). The clinical picture of patients with NAFLD prevailed such symptoms and complaints: flatulence in 43.59% of patients, weakness and pain in the right upper quadrant in 29.9% of patients. Fewer patients complained on discomfort in abdomen 28.21%, constipation 21.37% and feeling of bitterness in the mouth 21.37%. CONCLUSION: Clinical features of NAFLD are polysymptomatic. There are prevalence of dyspeptic syndromes (bloating met in 43.59% of patients, pain in right upper quadrant and discomfort in abdomen -29.91%, constipation- 28.21%, bitterness in mouth-21.37%. Determination of fatty liver index is very informative method of screening patients with hepatisteatosis. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I11 | 5295 | Intestinal disease | A gastrointestinal system disease that is located_in the intestine. http://en.wikipedia.org/wiki/Human_gastrointestinal_tract | disease of anatomical entity/gastrointestinal system disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |